Head-to-head evidence
AZD3427 vs AZD5462
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Heart Failure
Shared mechanism: Relaxin receptor (RXFP1) / relaxin · full Heart Failure pipeline
AZD3427
Developed by AstraZeneca
NCT04630067 · Phase 1 · completed
This is a randomized, double-blind, placebo-controlled dose-escalation safety study. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
AZD5462
Developed by AstraZeneca
NCT06299826 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, with 375 participants across three AZD5462 dose groups and a placebo group. Its primary endpoint was a surrogate echocardiographic measure, and no primary-outcome results or statistical comparison are currently available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: AZD3427's landscape · AZD5462's landscape